| Hannah Maina Mude Mishkin, MD | |
|
420 S 5th Ave, West Reading, PA 19611-2143 | |
| (484) 628-3637 | |
| Not Available |
| Full Name | Hannah Maina Mude Mishkin |
|---|---|
| Gender | Female |
| Speciality | Emergency Medicine |
| Location | 420 S 5th Ave, West Reading, Pennsylvania |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1215128541 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207P00000X | Emergency Medicine | MT18632 (Pennsylvania) | Secondary |
| 207P00000X | Emergency Medicine | MD434009 (Pennsylvania) | Primary |
| Entity Name | Tower Health Medical Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1609291350 PECOS PAC ID: 7618889213 Enrollment ID: O20040311000072 |
News Archive
Next week, more than 2,000 maternal-fetal medicine specialists (high-risk pregnancy physicians) will gather in Dallas for the Society for Maternal-Fetal Medicine's 38th Annual Meeting also called, The Pregnancy Meeting.
Several screening tests for cervical cancer have been developed in recent years. One technique uses immunofluorescent staining to determine the levels of biomarkers to indicate a cell is undergoing HPV-related cancerous growth.
Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
Centice Corporation, a pioneer in chemical verification of dispensed drug prescriptions and the manufacturer of the PASS Rx system, today launched a partner program to make available the PASS Rx® system to companies wanting to include unique prescription verification technology into workflow projects.
› Verified 6 days ago
| Entity Name | Reading Hospital |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1992387518 PECOS PAC ID: 7618886490 Enrollment ID: O20040408001076 |
News Archive
Next week, more than 2,000 maternal-fetal medicine specialists (high-risk pregnancy physicians) will gather in Dallas for the Society for Maternal-Fetal Medicine's 38th Annual Meeting also called, The Pregnancy Meeting.
Several screening tests for cervical cancer have been developed in recent years. One technique uses immunofluorescent staining to determine the levels of biomarkers to indicate a cell is undergoing HPV-related cancerous growth.
Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
Centice Corporation, a pioneer in chemical verification of dispensed drug prescriptions and the manufacturer of the PASS Rx system, today launched a partner program to make available the PASS Rx® system to companies wanting to include unique prescription verification technology into workflow projects.
› Verified 6 days ago
| Entity Name | Phoenixville Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1891866182 PECOS PAC ID: 5799796850 Enrollment ID: O20060606000128 |
News Archive
Next week, more than 2,000 maternal-fetal medicine specialists (high-risk pregnancy physicians) will gather in Dallas for the Society for Maternal-Fetal Medicine's 38th Annual Meeting also called, The Pregnancy Meeting.
Several screening tests for cervical cancer have been developed in recent years. One technique uses immunofluorescent staining to determine the levels of biomarkers to indicate a cell is undergoing HPV-related cancerous growth.
Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
Centice Corporation, a pioneer in chemical verification of dispensed drug prescriptions and the manufacturer of the PASS Rx system, today launched a partner program to make available the PASS Rx® system to companies wanting to include unique prescription verification technology into workflow projects.
› Verified 6 days ago
| Entity Name | Pottstown Clinic Company Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1649341934 PECOS PAC ID: 6406857184 Enrollment ID: O20070123000573 |
News Archive
Next week, more than 2,000 maternal-fetal medicine specialists (high-risk pregnancy physicians) will gather in Dallas for the Society for Maternal-Fetal Medicine's 38th Annual Meeting also called, The Pregnancy Meeting.
Several screening tests for cervical cancer have been developed in recent years. One technique uses immunofluorescent staining to determine the levels of biomarkers to indicate a cell is undergoing HPV-related cancerous growth.
Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
Centice Corporation, a pioneer in chemical verification of dispensed drug prescriptions and the manufacturer of the PASS Rx system, today launched a partner program to make available the PASS Rx® system to companies wanting to include unique prescription verification technology into workflow projects.
› Verified 6 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Hannah Maina Mude Mishkin, MD Po Box 13579, Reading, PA 19612-3579 Ph: (484) 628-0799 | Hannah Maina Mude Mishkin, MD 420 S 5th Ave, West Reading, PA 19611-2143 Ph: (484) 628-3637 |
News Archive
Next week, more than 2,000 maternal-fetal medicine specialists (high-risk pregnancy physicians) will gather in Dallas for the Society for Maternal-Fetal Medicine's 38th Annual Meeting also called, The Pregnancy Meeting.
Several screening tests for cervical cancer have been developed in recent years. One technique uses immunofluorescent staining to determine the levels of biomarkers to indicate a cell is undergoing HPV-related cancerous growth.
Exact Sciences Corp. today announced it has been awarded a $244,500 therapeutic discovery grant from the Internal Revenue Service to aid the company in its development of CologuardTM, an sDNA screening test aimed at detecting both colorectal cancers and pre-cancers.
Keryx Biopharmaceuticals, Inc. today announced that a manuscript entitled "Perifosine Plus Bortezomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients Previously Treated with Bortezomib: Results of a Multicenter Phase l/2 Trial" reporting Phase 1 / 2 combination activity of KRX-0401 (perifosine) in the treatment of advanced multiple myeloma (MM) patients, was selected for publication in the October 11, 2011 online edition of the Journal of Clinical Oncology.
Centice Corporation, a pioneer in chemical verification of dispensed drug prescriptions and the manufacturer of the PASS Rx system, today launched a partner program to make available the PASS Rx® system to companies wanting to include unique prescription verification technology into workflow projects.
› Verified 6 days ago
Liza Gergenti, MD Emergency Medicine Medicare: Accepting Medicare Assignments Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-3528 | |
Joshua Adam Werner, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-3637 | |
Eric Smith, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
James Sullivan, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Ray Morganti, M.D. Emergency Medicine Medicare: Medicare Enrolled Practice Location: 6th Ave & Spruce St, West Reading, PA 19611 Phone: 610-988-8218 | |
Dr. Joseph Patrick Corcoran Iv, MD Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 | |
Memu-iye Kamara, DO Emergency Medicine Medicare: Medicare Enrolled Practice Location: 420 S 5th Ave, West Reading, PA 19611 Phone: 484-628-8000 |